Hello,
Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:
- Meet this year's 30 leaders under 40 transforming healthcare;
- United Health Group's Optum is wading into the direct-to-consumer world;
- Moderna's CEO spelled out his M&A strategy and what the company is looking for in gene editing.
If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @lydiaramsey125. Let's get to it…

Thrive; Carrot Fertility; Oura; Deena Shakir; Samantha Lee/Insider
Meet the 30 young leaders forging a new future for the healthcare industry in 2021
- A generation of leaders is transforming the healthcare industry.
- They include doctors, scientists, execs, and founders who are improving how we keep people healthy.
- Out of hundreds of nominations, Insider selected 30 leaders under 40 transforming healthcare.

Optum CEO Andrew Witty
Reuters
The biggest US healthcare company is jumping into the red-hot direct-to-consumer prescription market

Reuters
- Industry giant UnitedHealth Group is pushing into the direct-to-consumer healthcare market.
- The company's Optum business is selling generic drugs and virtual care to people who pay with cash.
- The move brings new competition to digital-health upstarts such as Ro and Hims.

Moderna CEO, Stephane Bancel attends 2019 Forbes Healthcare Summit at the Jazz at Lincoln Center on December 05, 2019 in New York City.
Steven Ferdman/Getty Images
Moderna's CEO spells out its new M&A strategy, including what the $160 billion biotech is looking for in gene editing

Steven Ferdman/Getty Images
- Thinking beyond COVID-19, Moderna is planning to get into the gene therapy and editing space.
- CEO Stephane Bancel said he'd like to license in new enzymes to use in gene editing.
- A full acquisition of a gene-editing company is unlikely, he said, because of the rich valuations.
More stories we're reading:
- The CEO of the anti-aging foundation cofounded by Aubrey de Grey left amid an investigation into sexual harassment allegations against de Grey (Stat News)
- Rates of children hospitalized with COVID-19 have reached an all-time high in the US (Insider)
- What happens when algorithms get involved with opioid prescribing (Wired)
- How one woman overcame her vaccine hesitancy: 'You call them anti-vaxxers - I believe a lot of them are just afraid' (Insider)
- Lydia
Read the original article on Business Insider